208 related articles for article (PubMed ID: 9187846)
1. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma.
Fierro MT; Doveil GC; Quaglino P; Savoia P; Verrone A; Bernengo MG
Dermatology; 1997; 194(3):268-72. PubMed ID: 9187846
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
3. Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin).
Bertini M; Freilone R; Botto B; Calvi R; Gallamini A; Gatti AM; Liberati AM; Meneghini V; Orlandi E; Orsucci L; Pizzuti M; Rota Scalabrini D; Salvi F; Todeschini G; Vitolo U; Resegotti L
Haematologica; 1997; 82(3):309-13. PubMed ID: 9234577
[TBL] [Abstract][Full Text] [Related]
4. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
5. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Sweetenham JW; Mead GM; Whitehouse JM
J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
[TBL] [Abstract][Full Text] [Related]
6. A weekly alternating chemotherapy regimen with low toxicity for the treatment of aggressive lymphoma.
Bower M; Brock C; Gulliford T; O'Reilly SM; Smith DB; Newlands ES
Cancer Chemother Pharmacol; 1996; 38(1):106-9. PubMed ID: 8603443
[TBL] [Abstract][Full Text] [Related]
7. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
8. CA and leukemia group B 9251 protocol.
Zitter K; DeVos D
Radiol Technol; 1997; 68(5):423-5. PubMed ID: 9170185
[No Abstract] [Full Text] [Related]
9. [Primary cutaneous lymphoma--mycosis fungoides].
Nagatani T; Okazawa H; Mizuno H; Yanagi N; Miyazawa M; Baba N
Gan To Kagaku Ryoho; 1997 Jan; 24(1):23-9. PubMed ID: 9020941
[TBL] [Abstract][Full Text] [Related]
10. Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy.
Isogai R; Kawada A; Hashimoto K; Aragane Y; Tezuka T; Maeda Y; Kanamaru A
Dermatology; 2004; 209(3):243-5. PubMed ID: 15459544
[No Abstract] [Full Text] [Related]
11. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
12. Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma.
Avilés A; Nambo MJ; Neri N; Talavera A; Castañeda C; Murillo E; Cleto S; Huerta-Guzmán J
Med Oncol; 2004; 21(3):269-72. PubMed ID: 15456955
[TBL] [Abstract][Full Text] [Related]
13. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study.
Grozea PN; Jones SE; McKelvey EM; Coltman CA; Fisher R; Haskins CL
Cancer Treat Rep; 1979 Apr; 63(4):647-53. PubMed ID: 87277
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
Mugitani A; Tatsumi Y; Tanaka K; Yasui Y; Inoue T
Anticancer Res; 1999; 19(4C):3393-7. PubMed ID: 10629625
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
17. [Reye syndrome in a child having received chemotherapy].
Dubern B; Alessandri JL; Montbrun A; Attali T; Pilorget H; Samperiz S
Arch Pediatr; 1998 Mar; 5(3):342-3. PubMed ID: 10328010
[No Abstract] [Full Text] [Related]
18. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
19. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
[TBL] [Abstract][Full Text] [Related]
20. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.
Scarisbrick JJ; Child FJ; Clift A; Sabroe R; Whittaker SJ; Spittle M; Russell-Jones R
Br J Dermatol; 2001 May; 144(5):1010-5. PubMed ID: 11359390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
